Serotonin-Induced Contraction in Mesenteric Resistance Arteries
- 1 March 2002
- journal article
- Published by Wolters Kluwer Health in Hypertension
- Vol. 39 (3) , 825-829
- https://doi.org/10.1161/hy0302.104668
Abstract
Large arteries from hypertensive subjects are hyperresponsiveness to 5-hydroxytryptamine (5-HT). We tested the hypothesis that small arteries (225 micro ID) have a profile similar to conduit arteries, including signal transduction mechanisms and the 5-HT receptor subtype(s) mediating arterial contraction in normal and high blood pressure. Aorta and mesenteric arteries from Sprague-Dawley (232+/-6 micro ID), sham (229+/-7 micro ID; systolic blood pressure, 120+/-2 mm Hg), or deoxycorticosterone acetate (DOCA)-salt rats (255+/-11 micro ID, 192+/-8 mm Hg) were mounted in a wire-based myograph. In resistance arteries from Sprague-Dawley rats, the 5-HT2A receptor mediated contraction; agonists of the 5-HT1B, 5-HT1D, 5-HT1F, and 5-HT2B receptor were inactive. The tyrosine kinase inhibitor genistein (5 micromol/L, 4.8-fold rightward shift), PD 098,059 (10 micromol/L, 3.2-fold shift), phospholipase C inhibitor NCDC (100 micromol/L), and nifedipine (50 nmol/L) reduced maximum 5-HT-induced contraction in small arteries (4.5% and 53% control, respectively). As in aorta, 5-HT had a decrease in threshold (100-fold lower), increase in potency (11.6-fold leftward shift), and increase in efficacy (140% sham response) in small arteries from DOCA-salt rats compared with sham. Unlike in aorta, 5-HT-induced contraction in DOCA-salt small arteries was shifted competitively by the 5-HT2A receptor antagonist ketanserin (-log K(B) [mol/L] for both sham and DOCA-salt, 9.25+/-0.1), and contraction to the 5-HT2B agonist BW723C86 was not observed. Thus, the 5-HT2A receptor remains the contractile receptor in hypertension in small arteries. Although similarities were observed for large and small arteries, differences under the condition of DOCA-salt hypertension exist that may determine serotonergic compounds effective in lowering blood pressure.Keywords
This publication has 14 references indexed in Scilit:
- No contractile effect for 5‐HT1D and 5‐HT1F receptor agonists in human and bovine cerebral arteries: similarity with human coronary arteryBritish Journal of Pharmacology, 2000
- Expression of 5-HT2A and 5-HT1B receptor mRNA in blood vessels.Molecular and Cellular Biochemistry, 1999
- Characterization of LY344864 as a pharmacological tool to study 5-HT1F receptors: Binding affinities, brain penetration and activity in the neurogenic dural inflammation model of migraineLife Sciences, 1997
- Vascular receptors for 5-hydroxytryptamine: Distribution, function and classificationPharmacology & Therapeutics, 1994
- Contrasting Effects of Norepinephrine and 5-Hydroxytryptamine on Contractility of Abdominal Aorta of two Kidney-Two Clip Hypertensive Rats. Effects of Inhibitors of Arachidonic Acid Metabolic EnzymesClinical and Experimental Hypertension. Part A: Theory and Practice, 1990
- Serotoninergic mechanisms in hypertension. Focus on the effects of ketanserin.Hypertension, 1988
- Vascular responsiveness to serotonin metabolites in mineralocorticoid hypertension.Hypertension, 1987
- Hypersensitivity of mesenteric veins to 5‐hydroxytryptamine‐ and ketanserin‐induced reduction of portal pressure in portal hypertensive ratsBritish Journal of Pharmacology, 1986
- Direct and Sensitizing Effects of Serotonin Agonists and Antagonists on Vascular Smooth MuscleJournal of Cardiovascular Pharmacology, 1985
- Evidence that blood pressure reduction by serotonin antagonists is related to alpha receptor blockade in spontaneously hypertensive rats.Hypertension, 1983